Misplaced Pages

Flunitazene

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Designer drug with opioid effects

Pharmaceutical compound
Flunitazene
Legal status
Legal status
Identifiers
IUPAC name
  • N,N-diethyl-2--5-nitrobenzimidazol-1-yl]ethanamine
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC20H23FN4O2
Molar mass370.428 g·mol
3D model (JSmol)
SMILES
  • CCN(CC)CCN1C2=C(C=C(C=C2)(=O))N=C1CC3=CC=C(C=C3)F
InChI
  • InChI=1S/C20H23FN4O2/c1-3-23(4-2)11-12-24-19-10-9-17(25(26)27)14-18(19)22-20(24)13-15-5-7-16(21)8-6-15/h5-10,14H,3-4,11-13H2,1-2H3
  • Key:ZTWHIDCAGRMKTC-UHFFFAOYSA-N

Flunitazene (Fluonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is one of the least potent derivatives from this class to have appeared as a designer drug, with only around the same potency as morphine, but nevertheless has been sold since around 2020, and has been linked to numerous drug overdose cases.

See also

References

  1. Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG (August 2021). ""Etazene, safer than heroin and fentanyl": Non-fentanyl novel synthetic opioid listings on one darknet market". Drug and Alcohol Dependence. 225: 108790. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156. S2CID 235362241.
  2. "A review of the evidence on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids" (PDF). UK: Advisory Council on the Misuse of Drugs. July 2022.
  3. Walton SE, Krotulski AJ, Logan BK (March 2022). "A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS)". Journal of Analytical Toxicology. 46 (3): 221–231. doi:10.1093/jat/bkab117. PMC 8935987. PMID 34792157.
  4. Montanari E, Madeo G, Pichini S, Busardò FP, Carlier J (August 2022). "Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review". Therapeutic Drug Monitoring. 44 (4): 494–510. doi:10.1097/FTD.0000000000000970. PMID 35149665. S2CID 246776288.
  5. Schüller M, Lucic I, Leere Øiestad ÅM, Pedersen-Bjergaard S, Øiestad EL (September 2023). "High-throughput quantification of emerging nitazene benzimidazole opioid analogs by microextraction and UHPLC-MS/MS". Journal of Analytical Toxicology. 47 (9): 787–796. doi:10.1093/jat/bkad071. PMC 10714918. PMID 37700512.
  6. Balcaen M, Ventura M, Gil C, Luf A, Martins D, Cunha M, et al. (March 2023). "Challenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing". International Journal of Environmental Research and Public Health. 20 (5): 4628. doi:10.3390/ijerph20054628. PMC 10002093. PMID 36901637.
Opioid receptor modulators
μ-opioid
(MOR)
Agonists
(abridged;
full list)
Antagonists
δ-opioid
(DOR)
Agonists
Antagonists
κ-opioid
(KOR)
Agonists
Antagonists
Nociceptin
(NOP)
Agonists
Antagonists
Others
  • Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)


Stub icon

This analgesic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Flunitazene Add topic